![]() Hexavalent vaccines target six pathogens and are the cornerstone of infant immunization programs in many countries. The large amount of safety data gathered from clinical trials and from spontaneous adverse event reporting during 17 years of routine vaccination with Infanrix hexa supports its continued use in young children. There was no increased risk of sudden death after Infanrix hexa vaccination, consistent with what was shown in several other studies.Īs shown previously, seizures were more common when Infanrix hexa was given together with the pneumococcal conjugate vaccine, Prevnar 13, than when it was given alone. The most commonly reported adverse events were fever, crying and injection site redness and swellingĪn in-depth review of extensive limb swelling after Infanrix hexa vaccination revealed no safety concerns. We analyzed spontaneously reported adverse events after Infanrix hexa vaccinations between 20 Here we summarize 17 years of safety data for the Infanrix hexa vaccine. ![]() It is important to share up-to-date information on the safety of vaccines, particularly since concerns about vaccine safety in parents may lead to lower vaccination rates an disease outbreaks. One of these vaccines (the longest on the market) is called Infanrix hexa it has been available for infants and toddlers since 2000.Īfter a vaccine is included in a country’s routine vaccination program, its safety is constantly checked this is done in clinical trials and through spontaneous reporting of adverse events after vaccination. The cornerstone of childhood vaccination in many countries worldwide is a vaccine that protects against several diseases: diphtheria, tetanus, whooping cough, hepatitis B, polio and Haemophilus influenzae type b infections (such as meningitis). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |